<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934102</url>
  </required_header>
  <id_info>
    <org_study_id>P-368-C-103</org_study_id>
    <nct_id>NCT00934102</nct_id>
  </id_info>
  <brief_title>Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses</brief_title>
  <acronym>QUINCE</acronym>
  <official_title>Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses (P/318/08/C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIBA VISION</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Waterloo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the ophthalmic compatibility of three different
      silicone hydrogel lenses worn on an overnight basis for six nights.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Front Surface Lens Deposits</measure>
    <time_frame>Period 2, Day 6</time_frame>
    <description>Protein and lipid deposits on the contact lens surface as assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye. Deposits were graded on a scale of 0 to 4 with 0 being none and 4 being severe.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Lotrafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotrafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Narafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Galyfilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Galyfilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narafilcon A contact lens</intervention_name>
    <description>Investigational, silicone hydrogel, spherical soft contact lens</description>
    <arm_group_label>Narafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon A contact lens</intervention_name>
    <description>Commercially marketed, silicone hydrogel, spherical soft contact lens</description>
    <arm_group_label>Lotrafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Galyfilcon A contact lens</intervention_name>
    <description>Commercially marketed, silicone hydrogel, spherical soft contact lens</description>
    <arm_group_label>Galyfilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is at least 17 years of age and has full legal capacity to volunteer

          -  Is correctable to a visual acuity of 20/30 or better (in each eye) with their habitual
             vision correction

          -  Has had an ocular examination in the last two years

          -  Is a current soft (hydrogel or silicone hydrogel) contact lens wearer

          -  Has clear corneas and no active ocular disease

          -  Can be successfully fit with the lenses to be used in the study

          -  Other protocol-defined inclusion/exclusion criteria may apply

        Exclusion Criteria:

          -  Is pregnant or lactating

          -  Has undergone corneal refractive surgery

          -  Currently wears lenses on an extended wear basis or was on extended wear within six
             months prior to the study

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre for Contact Lens Research: University of Waterloo</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <results_first_submitted>November 1, 2010</results_first_submitted>
  <results_first_submitted_qc>November 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 1, 2010</results_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 57 subjects screened for the study, 11 did not start Period 1 due to personal reasons (7) and non-suitability (4). Period 1 established Day One measurements in order to monitor changes during Period 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Narafilcon A / Lotrafilcon A</title>
          <description>Narafilcon A experimental contact lens randomly assigned to one eye, with Lotrafilcon A commercial contact lens assigned to the fellow eye for contralateral wear.</description>
        </group>
        <group group_id="P2">
          <title>Narafilcon A / Galyfilcon A</title>
          <description>Narafilcon A experimental contact lens randomly assigned to one eye, with Galyfilcon A commercial contact lens assigned to the fellow eye for contralateral wear.</description>
        </group>
        <group group_id="P3">
          <title>Lotrafilcon A / Galyfilcon A</title>
          <description>Lotrafilcon A commercial contact lens randomly assigned to one eye, with Galyfilcon A commercial contact lens assigned to the fellow eye for contralateral wear.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, One Night of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2, 7 Days/6 Nights of Wear</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>This reporting group includes all subjects who were screened for the study, whether or not they subsequently were dispensed.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.23" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Front Surface Lens Deposits</title>
        <description>Protein and lipid deposits on the contact lens surface as assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye. Deposits were graded on a scale of 0 to 4 with 0 being none and 4 being severe.</description>
        <time_frame>Period 2, Day 6</time_frame>
        <population>Per Protocol. Only the data from participants who completed all study visits were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon A</title>
            <description>Commercially marketed, silicone hydrogel, spherical soft contact lens, worn on an extended wear basis.</description>
          </group>
          <group group_id="O2">
            <title>Narafilcon A</title>
            <description>Investigational, silicone hydrogel, spherical soft contact lens, worn on an extended wear basis.</description>
          </group>
          <group group_id="O3">
            <title>Galyfilcon A</title>
            <description>Commercially marketed, silicone hydrogel, spherical soft contact lens, worn on an extended wear basis.</description>
          </group>
        </group_list>
        <measure>
          <title>Front Surface Lens Deposits</title>
          <description>Protein and lipid deposits on the contact lens surface as assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye. Deposits were graded on a scale of 0 to 4 with 0 being none and 4 being severe.</description>
          <population>Per Protocol. Only the data from participants who completed all study visits were analyzed.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.35"/>
                    <measurement group_id="O2" value="0.78" spread="0.67"/>
                    <measurement group_id="O3" value="0.77" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the duration of the trial: 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lotrafilcon A</title>
          <description>Commercially marketed, silicone hydrogel, spherical soft contact lens, worn on an extended wear basis.</description>
        </group>
        <group group_id="E2">
          <title>Narafilcon A</title>
          <description>Experimental, silicone hydrogel, spherical soft contact lens, worn on an extended wear basis.</description>
        </group>
        <group group_id="E3">
          <title>Galyfilcon A</title>
          <description>Commercially marketed, silicone hydrogel, spherical soft contact lens, worn on an extended wear basis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No distribution of trial-specific information without express written permission of director.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig Woods, PhD, FAAO / Research Manager</name_or_title>
      <organization>University of Waterloo</organization>
      <phone>1-519-888-4742</phone>
      <email>cclr2@uwaterloo.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

